CLAIMS

1. An agent for treating glaucoma or ocular hypertension, comprising an FP agonist as an active ingredient adapted to be administered in combination with timolol ~~a β-blocker~~ or a pharmaceutically acceptable salt thereof, wherein

the FP agonist is 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate.

~~2. The agent according to claim 1, wherein the β-blocker is timolol, carteolol, levobunolol, betaxolol, nipradilol, or befunolol.~~

~~3. The agent according to claim 1 or 2, wherein the β-blocker is timolol.~~

2~~4~~. The agent according to ~~any one of~~ claim~~s~~ 1~~ to 3~~, wherein the timolol β-blocker ~~or~~ a pharmaceutically acceptable salt thereof and 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate are administered separately or concurrently.

3~~5~~. A pharmaceutical composition for treating glaucoma or ocular hypertension, comprising 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate and timolol~~a β-blocker~~ or a pharmaceutically acceptable salt thereof adapted to be administered in combination.

~~6. The pharmaceutical composition according to claim 5, wherein the β-blocker is timolol, carteolol, levobunolol, betaxolol, nipradilol, or befunolol.~~

~~7. The pharmaceutical composition according to claim 5 or 6, wherein the β-blocker is timolol.~~

4~~8~~. The pharmaceutical composition according to ~~any one of~~ claim~~s~~ 3~~5 to 7~~, which is an eye drop or an eye ointment.

5~~9~~. The pharmaceutical composition according to ~~any one of~~ claim~~s~~ 3 or claim 4~~5 to 8~~, which is a compounding agent.

6~~10~~. Use of an effective amount of 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b] oxepin-3-yl}butanoate and timolol or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament ~~A method~~ for treating glaucoma or ocular hypertension, ~~the method comprising administering in combination to~~in a patient in need thereof ~~treating glaucoma or ocular hypertension an effective amount of 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate and a β-blocker or a pharmaceutically acceptable salt thereof, separately or concurrently~~.

7. Use of an effective amount of 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b] oxepin-3-yl}butanoate in the manufacture of a medicament for treating glaucoma or ocular hypertension, in a patient in need thereof, wherein the medicament is to be separately administered with timolol or a pharmaceutically acceptable salt thereof.

~~11. A method for treating glaucoma or ocular hypertension, the method comprising administering to a patient in need of treating glaucoma or ocular hypertension an effective amount of 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate, the method further comprising administering an effective amount of a β-blocker or a pharmaceutically acceptable salt thereof~~.

~~8~~12. 2-Propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate ~~that is~~for use~~d for~~ in treating glaucoma or ocular hypertension in combination with a timolol ~~β-blocker~~ or a pharmaceutically acceptable salt thereof.

~~13. A use of 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate for the manufacture of an agent for treating glaucoma or ocular hypertension adapted to be administered in combination with a β-blocker or a pharmaceutically acceptable salt thereof.~~